← Leaderboards
Benyi Li
University Of Kansas Lawrence
$642,749
Attributed
$642,749
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $197.1K · FY2005–15$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$642,749 · 7
By mechanism
R21$361,268 · 1
P20$281,481 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Kansas Lawrence
Same institution · by research overlap
- Erik A Lundquist$9,913,591
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateProstateNovel StrategiesLeadComputer Retrieval Of Information On Scientific Projects DatabaseFundingCancer TherapyResourcesUnited States National Institutes Of HealthSourceInhibitor/AntagonistSignal TransductionInstitutionCancer CellNovel TherapeuticsGrantResearch PersonnelPlayCessation Of LifeHomologous GeneAndrogensCenters Of Research ExcellenceDisease ProgressionFoundations
Grant awards (8)
Prostate-targeted CRMP4 saRNA as anti-metastatic therapy$164,213
R21 · FY2015 · CA · contact PI
Prostate-targeted CRMP4 saRNA as anti-metastatic therapy$197,055
R21 · FY2014 · CA · contact PI
P13K P110BETA IN PROSTATE CANCER PROGRESSION$40,510
P20 · FY2009 · RR · contact PI
P13K P110BETA IN PROSTATE CANCER PROGRESSION$72,038
P20 · FY2008 · RR · contact PI
ROLE OF SHP-2 IN GSK-3BETA INHIBITOR-INDUCED TRAIL SENSITIZATION$69,606
P20 · FY2007 · RR · contact PI
P13K P110BETA IN PROSTATE CANCER PROGRESSION$21,370
P20 · FY2007 · RR · contact PI
ROLE OF SHP-2 IN GSK-3BETA INHIBITOR-INDUCED TRAIL SENSITIZATION$62,774
P20 · FY2006 · RR · contact PI
ROLE OF SHP-2 IN GSK-3BETA INHIBITOR-INDUCED TRAIL SENSITIZATION$15,183
P20 · FY2005 · RR